Orexo AB (ORX) - Net Assets

Latest as of March 2026: Skr364.70 Million SEK ≈ $39.25 Million USD

Based on the latest financial reports, Orexo AB (ORX) has net assets worth Skr364.70 Million SEK (≈ $39.25 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr610.40 Million ≈ $65.69 Million USD) and total liabilities (Skr245.70 Million ≈ $26.44 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check tangible net worth ratio of Orexo AB to evaluate the tangible quality of the company's equity base.

Key Net Assets Metrics

Metric Value
Current Net Assets Skr364.70 Million
% of Total Assets 59.75%
Annual Growth Rate 13.72%
5-Year Change 40.33%
10-Year Change 58.11%
Growth Volatility 113.26

Orexo AB - Net Assets Trend (2002–2025)

This chart illustrates how Orexo AB's net assets have evolved over time, based on quarterly financial data. See how many days can Orexo AB fund operations to measure how many days the company can operate on defensive assets alone.

Annual Net Assets for Orexo AB (2002–2025)

The table below shows the annual net assets of Orexo AB from 2002 to 2025. For live valuation and market cap data, see ORX market cap.

Year Net Assets Change
2025-12-31 Skr490.60 Million
≈ $52.80 Million		 +488.44%
2024-12-31 Skr-126.30 Million
≈ $-13.59 Million		 -314.43%
2023-12-31 Skr58.90 Million
≈ $6.34 Million		 -69.62%
2022-12-31 Skr193.90 Million
≈ $20.87 Million		 -44.54%
2021-12-31 Skr349.60 Million
≈ $37.62 Million		 -37.40%
2020-12-31 Skr558.50 Million
≈ $60.10 Million		 -20.94%
2019-12-31 Skr706.40 Million
≈ $76.02 Million		 +48.37%
2018-12-31 Skr476.10 Million
≈ $51.24 Million		 +44.67%
2017-12-31 Skr329.10 Million
≈ $35.42 Million		 +6.06%
2016-12-31 Skr310.30 Million
≈ $33.39 Million		 +16.45%
2015-12-31 Skr266.46 Million
≈ $28.68 Million		 -41.44%
2014-12-31 Skr455.02 Million
≈ $48.97 Million		 +181.82%
2013-12-31 Skr161.46 Million
≈ $17.38 Million		 -15.55%
2012-12-31 Skr191.19 Million
≈ $20.58 Million		 -38.54%
2011-12-31 Skr311.10 Million
≈ $33.48 Million		 -33.56%
2010-12-31 Skr468.24 Million
≈ $50.39 Million		 -14.66%
2009-12-31 Skr548.66 Million
≈ $59.04 Million		 -3.71%
2008-12-31 Skr569.78 Million
≈ $61.32 Million		 -15.12%
2007-12-31 Skr671.25 Million
≈ $72.24 Million		 +106.95%
2006-12-31 Skr324.35 Million
≈ $34.91 Million		 -4.30%
2005-12-31 Skr338.91 Million
≈ $36.47 Million		 +326.64%
2004-12-31 Skr79.44 Million
≈ $8.55 Million		 +121.38%
2003-12-31 Skr35.88 Million
≈ $3.86 Million		 +40.62%
2002-12-31 Skr25.52 Million
≈ $2.75 Million		 --

Equity Component Analysis

This analysis shows how different components contribute to Orexo AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 134138200000.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2025)

Component Amount Percentage
Common Stock Skr15.20 Million 3.10%
Other Components Skr1.84 Billion 374.56%
Total Equity Skr490.60 Million 100.00%

Orexo AB Competitors by Market Cap

The table below lists competitors of Orexo AB ranked by their market capitalization.

Company Market Cap
Fortress Biotech Inc
NASDAQ:FBIO
 $79.39 Million
Definitive Healthcare Corp
NASDAQ:DH
 $79.40 Million
Azaria Rental SOCIMI S.A.
MC:YAZR
 $79.42 Million
Biodesix Inc
NASDAQ:BDSX
 $79.44 Million
Drilling Tools International Corp.
NASDAQ:DTI
 $79.38 Million
Vera Bradley Inc
NASDAQ:VRA
 $79.34 Million
VIVANI MED.INC. NEW O.N.
F:U5P
 $79.34 Million
The Sandesh Limited
NSE:SANDESH
 $79.29 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Orexo AB's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2024 to 2025, total equity changed from -126,300,000 to 490,600,000, a change of 616,900,000.
  • Net loss of 129,800,000 reduced equity.
  • Other comprehensive income decreased equity by 32,799,999.
  • Other factors increased equity by 779,499,999.

Equity Change Factors (2024 to 2025)

Factor Impact Contribution
Net Income Skr-129.80 Million -26.46%
Other Comprehensive Income Skr-32.80 Million -6.69%
Other Changes Skr779.50 Million +158.89%
Total Change Skr- %

Book Value vs Market Value Analysis

This analysis compares Orexo AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 1.48x
  • The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
  • The price-to-book ratio has increased from 0.02x to 1.48x over the analyzed period, suggesting growing market confidence.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2002-12-31 Skr974.60 Skr21.00 x
2003-12-31 Skr1222.76 Skr21.00 x
2004-12-31 Skr2094.50 Skr21.00 x
2005-12-31 Skr25.52 Skr21.00 x
2006-12-31 Skr24.21 Skr21.00 x
2007-12-31 Skr44.41 Skr21.00 x
2008-12-31 Skr25.10 Skr21.00 x
2009-12-31 Skr24.14 Skr21.00 x
2010-12-31 Skr18.36 Skr21.00 x
2011-12-31 Skr11.45 Skr21.00 x
2012-12-31 Skr5.96 Skr21.00 x
2013-12-31 Skr4.98 Skr21.00 x
2014-12-31 Skr13.54 Skr21.00 x
2015-12-31 Skr7.73 Skr21.00 x
2016-12-31 Skr8.97 Skr21.00 x
2017-12-31 Skr9.50 Skr21.00 x
2018-12-31 Skr13.57 Skr21.00 x
2019-12-31 Skr19.98 Skr21.00 x
2020-12-31 Skr16.24 Skr21.00 x
2021-12-31 Skr10.19 Skr21.00 x
2022-12-31 Skr5.64 Skr21.00 x
2023-12-31 Skr1.71 Skr21.00 x
2024-12-31 Skr-3.66 Skr21.00 x
2025-12-31 Skr14.17 Skr21.00 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Orexo AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): -26.46%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: -499.23%
  • • Asset Turnover: 0.02x
  • • Equity Multiplier: 2.66x
  • Recent ROE (-26.46%) is above the historical average (-41.24%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2002 -81.53% -702.57% 0.09x 1.30x Skr-23.35 Million
2003 -76.90% -129.18% 0.47x 1.26x Skr-31.18 Million
2004 -20.07% -18.39% 0.82x 1.33x Skr-23.89 Million
2005 -12.76% -69.36% 0.17x 1.10x Skr-77.14 Million
2006 -10.16% -24.97% 0.35x 1.17x Skr-65.38 Million
2008 -18.09% -44.16% 0.33x 1.23x Skr-160.03 Million
2009 -17.88% -41.54% 0.36x 1.18x Skr-152.95 Million
2010 -19.06% -42.40% 0.30x 1.52x Skr-136.07 Million
2011 -126.01% -196.38% 0.37x 1.76x Skr-423.12 Million
2012 -44.91% -26.32% 0.68x 2.52x Skr-104.98 Million
2013 -95.96% -36.09% 0.56x 4.78x Skr-171.08 Million
2014 -12.44% -9.92% 0.47x 2.69x Skr-102.09 Million
2015 -74.30% -30.77% 0.63x 3.81x Skr-224.63 Million
2016 9.35% 4.11% 0.69x 3.28x Skr-2.03 Million
2017 7.05% 3.60% 0.64x 3.05x Skr-9.71 Million
2018 28.96% 17.61% 0.61x 2.70x Skr90.29 Million
2019 31.02% 25.94% 0.56x 2.13x Skr148.46 Million
2020 -15.11% -12.72% 0.54x 2.21x Skr-140.25 Million
2021 -63.93% -39.56% 0.44x 3.64x Skr-258.46 Million
2022 -91.59% -28.45% 0.56x 5.72x Skr-196.99 Million
2023 -217.83% -20.08% 0.81x 13.35x Skr-134.19 Million
2024 0.00% -34.41% 0.99x 0.00x Skr-190.37 Million
2025 -26.46% -499.23% 0.02x 2.66x Skr-178.86 Million

Industry Comparison

This section compares Orexo AB's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

  • Industry: Drug Manufacturers - Specialty & Generic
  • Average net assets among peers: $250,554,382
  • Average return on equity (ROE) among peers: -189.92%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Orexo AB (ORX) Skr364.70 Million -81.53% 0.67x $79.38 Million
BioGaia AB (publ) (BIOG-B) $132.42 Million 27.28% 0.17x $1.25 Billion
Enzymatica publ AB (ENZY) $124.97 Million -36.32% 0.26x $65.83 Million
Enorama Pharma AB (ERMA) $1.78 Million -1345.02% 22.02x $2.69 Million
Gabather AB (publ) (GABA) $33.19 Million -23.79% 0.05x $2.48 Million
Klaria Pharma Holding AB (KLAR) $69.42 Million -77.12% 0.70x $20.99 Million
Moberg Pharma AB (publ) (MOB) $15.23 Million -232.05% 0.48x $46.74 Million
Nanexa AB (NANEXA) $101.53 Million -11.22% 0.36x $77.75 Million
Newbury Pharmaceuticals AB (NEWBRY) $68.77 Million -21.33% 0.26x $6.28 Million
Swedish Orphan Biovitrum AB (publ) (SOBI) $1.71 Billion 10.32% 0.60x $16.38 Billion

About Orexo AB

ST:ORX Sweden Drug Manufacturers - Specialty & Generic
Market Cap
$79.38 Million
Skr737.67 Million SEK
Market Cap Rank
#20191 Global
#360 in Sweden
Share Price
Skr21.00
Change (1 day)
+0.00%
52-Week Range
Skr18.00 - Skr41.60
All Time High
Skr85.70
Categories
Companies in Sweden Drug Manufacturers - Specialty & Generic
About

Orexo AB (publ), a pharmaceutical company, provides advance treatments for severe diseases and life-saving rescue medications in the United States, European Union, the United Kingdom, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; Edluar for the treatment of insomnia; and Diabac… Read more